• 繁

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    How New CFO Appointment Will Impact Avantor (AVTR) Investors

    Simply Wall St·10/02/2026 23:22:51
    語音播報
    • Avantor appointed Todd Garner as Chief Financial Officer and Executive Vice President on September 21, 2026. He is responsible for global finance functions, including planning, accounting, treasury, tax, investor relations and internal audit, while Steve Eck returns full time to his Chief Accounting Officer role.
    • Garner’s three decades in senior finance roles at CONMED and C. R. Bard, including investor relations and divisional CFO posts, could influence how Avantor executes its Revival program and communicates around leverage, free cash flow and organic growth targets.
    • We will look at how Avantor's investment narrative may shift as Todd Garner takes over the finance organization and investor messaging.

    Scan how Avantor’s CFO transition compares with other financially disciplined businesses by reviewing the hand picked 31 resilient stocks with low risk scores that may better align with your risk profile.

    Avantor Investment Narrative Recap

    Owning Avantor means buying into the Revival program, the digital push around vwr.com, and a gradual clean up of the balance sheet, while the business works through softness in biotech, academia, and large pharma budgets. The new CFO appointment does not change that core thesis overnight. The more immediate swing factor still sits with execution on margins, free cash flow, and order conversion.

    The biggest operational risk remains competitive pressure in lab distribution combined with external cost headwinds that are already expected to compress adjusted EBITDA margins in 2026. Interest coverage is another watchpoint given current earnings. Todd Garner’s arrival looks incremental rather than transformational for that near term risk reward balance.

    The upcoming third quarter 2026 earnings release on October 28 is the cleanest near term checkpoint for this CFO transition. Investors will likely focus on whether Avantor reaffirms free cash flow guidance of US$500 million to US$550 million for 2026 and stays on track with the goal to move adjusted net leverage below 3x using that cash generation.

    This same update should give a clearer read on Revival progress, vwr.com traction, and order trends in Bioscience & Medtech Products, including the targeted book to bill above 1.1x. With a new finance leader in place, the tone and granularity of commentary around margins, inflation headwinds, and cost savings may matter almost as much as the reported numbers.

    Avantor's current analyst narrative points to revenue of US$7.1b and earnings of US$651.0 million by 2029. That profile is built on forecast revenue growth of 2.8% per year and an earnings swing of about US$1.23b from a loss of US$578.0 million today to the 2029 consensus level.

    Uncover why Avantor's fair value indicates a 5% potential downside to its current price, which leaves little room for error.

    NYSE:AVTR 1-Year Stock Price Chart
    NYSE:AVTR 1-Year Stock Price Chart

    Exploring Other Perspectives

    Some of the most optimistic analysts frame the Todd Garner hire as a potential accelerator for balance sheet decisions rather than just a finance reshuffle. Before this news, the bullish camp was already modeling about US$7.2b of revenue and US$589.9 million of earnings by 2029. That is far more upbeat than consensus and shows how far opinions can spread. You can use this CFO change as a trigger to compare several viewpoints and decide which story around Avantor feels closest to your own expectations.

    Explore another Avantor fair value estimate, including one that suggests as much as 11% upside from the current price.

    Reach Your Own Conclusion

    Disagree with existing narratives? Extraordinary investment outcomes rarely come from following the herd, so rely on your own analysis.

    Looking For More Investment Ideas Beyond Avantor?

    If the Avantor story has sharpened your thinking but you want a broader watchlist, the Simply Wall St Screener can help you quickly zero in on other companies that fit your style and risk tolerance.

    • For investors who care most about resilience and capital preservation, you can review a curated set of companies with relatively low risk profiles through the 31 resilient stocks with low risk scores.
    • If income is your focus, you can scan for stocks offering robust yields and payout histories using the 7 dividend fortresses.
    • Readers hunting for quality that is not yet widely followed can comb through a carefully filtered pool of under-the-radar opportunities using the 19 high quality undiscovered gems.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.